Antibodies in blood soon after COVID-19 onset may predict severity

by Bruce Goldman,Stanford University Medical CenterAn illustration of antlbodies surrounding a virus.Antibodies are proteins shaped, roughly speaking, like two-branched trees. They’re prod

Updated on: April 10,2024

Antibodies in blood soon after COVID-19 onset may predict severity

by Bruce Goldman,Stanford University Medical CenterAn illustration of antlbodies surrounding a virus.Antibodies are proteins shaped, roughly speaking, like two-branched trees. They’re prod

Updated on:April 10,2024

HDL composition may help predict health risks and design therapeutics

by Pat Bailey,UC DavisNutrition researcher Angela Zivkovic and colleagues have found that the amounts and specific structure of complex sugars called glycans can powerfully influence the body’s

Updated on: April 16,2024

HDL composition may help predict health risks and design therapeutics

by Pat Bailey,UC DavisNutrition researcher Angela Zivkovic and colleagues have found that the amounts and specific structure of complex sugars called glycans can powerfully influence the body’s

Updated on:April 16,2024

Patients with rheumatoid arthritis have increased anxiety during pandemic

For patients with rheumatoid arthritis (RA), anxiety increased during the COVID-19 pandemic, as did suspected depression, according to a letter to the editor published online Jan. 27 inRheumatol

Updated on: June 28,2024

Patients with rheumatoid arthritis have increased anxiety during pandemic

For patients with rheumatoid arthritis (RA), anxiety increased during the COVID-19 pandemic, as did suspected depression, according to a letter to the editor published online Jan. 27 inRheumatol

Updated on:June 28,2024

FDA approves first interchangeable biosimilar for inflammatory diseases

(HealthDay)—The first interchangeable biosimilar product to Humira (adalimumab) was approved by the U.S. Food and Drug Administration on Oct. 15, the agency announced Monday.Cyltezo (adalimumab-adbm),

Updated on: June 17,2024

FDA approves first interchangeable biosimilar for inflammatory diseases

(HealthDay)—The first interchangeable biosimilar product to Humira (adalimumab) was approved by the U.S. Food and Drug Administration on Oct. 15, the agency announced Monday.Cyltezo (adalimumab-adbm),

Updated on:June 17,2024

Epigenetics alters genes in rheumatoid arthritis

by University of California - San DiegoIn this artist's rendering, a DNA molecule is methylated on both strands at the center cytosine. DNA methylation plays an important role in epigenetic g

Updated on: March 24,2024

Epigenetics alters genes in rheumatoid arthritis

by University of California - San DiegoIn this artist's rendering, a DNA molecule is methylated on both strands at the center cytosine. DNA methylation plays an important role in epigenetic g

Updated on:March 24,2024

First-in-human trial with CAR macrophages shows promise targeting solid tumors

by Caren Begun,University of PennsylvaniaCredit: Pixabay/CC0 Public DomainPreliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability a

Updated on: April 09,2024

First-in-human trial with CAR macrophages shows promise targeting solid tumors

by Caren Begun,University of PennsylvaniaCredit: Pixabay/CC0 Public DomainPreliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability a

Updated on:April 09,2024

T-cell dysfunction increases cancer risk in obese populations, researchers say

bySaint Louis UniversityCD8+T cell dysfunction in the obese tumor microenvironment. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-47359-5Researchers at Saint Loui

Updated on: November 24,2024

T-cell dysfunction increases cancer risk in obese populations, researchers say

bySaint Louis UniversityCD8+T cell dysfunction in the obese tumor microenvironment. Credit:Nature Communications(2024). DOI: 10.1038/s41467-024-47359-5Researchers at Saint Loui

Updated on:November 24,2024

Severe reaction to pneumococcal vaccines in patients with CAPS

(HealthDay)—Pneumococcal vaccines can trigger a severe local and systemic inflammatory reaction in patients with cryopyrin-associated periodic syndromes (CAPS), according to a study published in the F

Updated on: April 17,2024

Severe reaction to pneumococcal vaccines in patients with CAPS

(HealthDay)—Pneumococcal vaccines can trigger a severe local and systemic inflammatory reaction in patients with cryopyrin-associated periodic syndromes (CAPS), according to a study published in the F

Updated on:April 17,2024

Long-term rituximab safe for patients with wegener's

Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiitis (GPA; Wegener&#3

Updated on: March 28,2024

Long-term rituximab safe for patients with wegener's

Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiitis (GPA; Wegener&#3

Updated on:March 28,2024

Adherence to mediterranean diet not linked to risk of RA

(HealthDay)—Adherence to a Mediterranean diet is not associated with incidence of rheumatoid arthritis (RA) in U.S. women, according to a study published in the May issue ofArthritis Care &

Updated on: April 08,2024

Adherence to mediterranean diet not linked to risk of RA

(HealthDay)—Adherence to a Mediterranean diet is not associated with incidence of rheumatoid arthritis (RA) in U.S. women, according to a study published in the May issue ofArthritis Care &

Updated on:April 08,2024

Upadacitinib beats placebo for psoriatic arthritis

For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of theNew England J

Updated on: May 26,2024

Upadacitinib beats placebo for psoriatic arthritis

For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of theNew England J

Updated on:May 26,2024

A new, potent weapon against lymphomas

by Max Delbrück Center for Molecular MedicineAnti-CXCR5 CAR-T cells (green) attack lymphoma cells (magenta) within the stroma cell network of the B cell follicle (light blue). Credit: AG Höpken /

Updated on: May 05,2024

A new, potent weapon against lymphomas

by Max Delbrück Center for Molecular MedicineAnti-CXCR5 CAR-T cells (green) attack lymphoma cells (magenta) within the stroma cell network of the B cell follicle (light blue). Credit: AG Höpken /

Updated on:May 05,2024